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Diabetes-induced 
hypomagnesemia is not modulated 
by metformin treatment in mice
steef Kurstjens1, Hacene Bouras1,2, Caro overmars-Bos  1, Mohamed Kebieche3, 
René J. M. Bindels1, Joost G. J. Hoenderop1 & Jeroen H. F. de Baaij  1
Approximately 30% of patients with type 2 diabetes mellitus (T2D) have hypomagnesemia (blood 
magnesium (Mg2+) concentration <0.7 mmol/L). In T2D patients, treatment with metformin is 
associated with reduced blood Mg2+ levels. To investigate how T2D and metformin affect Mg2+ 
homeostasis db/m and db/db mice were treated with metformin or placebo. Mice were housed in 
metabolic cages to measure food and water intake, and to collect urine and feces. Serum and urinary 
Mg2+ concentrations were determined and mRNA expression of magnesiotropic genes was determined 
in kidney and distal colon using RT-qPCR. Db/db mice had significantly lower serum Mg2+ levels than 
db/m mice. Mild hypermagnesuria was observed in the db/db mice at two weeks, but not at four 
weeks. Metformin-treatment had no effect on the serum Mg2+ concentration and on the urinary Mg2+ 
excretion. Both in kidney and distal colon of db/db mice, there was a compensatory upregulation in the 
mRNA expression of magnesiotropic genes, such as transient receptor potential melastatin 6 (Trpm6), 
whereas metformin treatment did not affect gene expression levels. In conclusion, we show that T2D 
causes hypomagnesemia and that metformin treatment has no effect on Mg2+ homeostasis in mice.
Approximately 30% of patients with type 2 diabetes mellitus (T2D) have hypomagnesemia (blood magnesium 
(Mg2+) <0.7 mmol/L)1,2. Hypomagnesemia has serious clinical consequences as it increases the risk of complica-
tions such as retinopathy, nephropathy, micro and macrovascular disease and foot ulceration3,4. Moreover, Mg2+ 
deficiency is correlated with insulin resistance, abrogated glucose metabolism and an increased risk of developing 
T2D5–7. However, the etiology and underlying mechanisms of hypomagnesemia in T2D patients remains largely 
unknown8.
As Mg2+ is necessary for the activity of over 600 enzymes, it plays numerous vital physiological functions 
including macromolecule synthesis, energy balance and DNA transcription9. Moreover, Mg2+ stabilizes ATP and 
is required for its phosphor transfer reactions10.
The intestine and kidney collaboratively regulate Mg2+ balance and maintain its blood concentrations within 
a narrow range11,12. In the gut, the bulk of Mg2+ absorption occurs in the small intestine via paracellular (passive) 
transport11. In the colon, the final absorption of Mg2+ takes place by an active transcellular mechanism through 
transient receptor potential melastatin type 6/7 (TRPM6/TRPM7) cation channels9. In the kidney, 95–99% of 
filtered Mg2+ is reabsorbed under physiological circumstances9. Approximately 85% of the filtered Mg2+ is reab-
sorbed paracellularly by the proximal tubule and the thick ascending loop of Henle (TAL), where transport relies 
on tight junction permeability13,14. Active transport in the distal convoluted tubule (DCT) determines the final 
urinary Mg2+ concentration, as this is the final segment where Mg2+ is reabsorbed15. In physiological conditions, 
the DCT reclaims 5–10% of filtered Mg2+ transcellularly via TRPM6/7 channels14,16. The expression and/or the 
activity of TRPM6 is affected by SNPs, dietary Mg2+ intake, drugs and hormones, such as insulin and epidermal 
growth factor (EGF)14,17–20. SNPs in TRPM6 that impair its response to insulin have been associated with an 
increased risk of developing T2D and gestational diabetes7,19.
Metformin, the first-line pharmacotherapy in T2D21, suppresses hepatic gluconeogenesis and improves insu-
lin sensitivity22. Therefore, its major clinical benefit is reducing blood glucose levels with only a minimal risk of 
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hypoglycemia23,24. The most common side effects of metformin treatment are lactic acidosis, nausea and diar-
rhea25. Recent cohort studies showed that metformin use in T2D patients is associated with reduced blood Mg2+ 
levels1,26. However, the mechanism that underlies this correlation has not yet been elucidated. To investigate 
how T2D and metformin affect Mg2+ homeostasis, control (db/m) and diabetic (db/db) mice were treated with 
placebo or metformin for four weeks. Serum and urinary electrolytes were measured and mRNA expression of 
magnesiotropic genes was evaluated in kidney and distal colon.
Methods
Animal study. The animal study was approved by the animal ethics board of the Radboud University 
Nijmegen (RU DEC 2015-0073) and by the Dutch Central Commission for Animal Experiments (CCD, 
AVD103002015239). Experimental procedures were conducted in accordance with the institutional guidelines 
and in compliance with Dutch and European laws and policies. Twenty diabetic (db/db) and twenty control 
(db/m) male mice (Charles River, Germany), aged 8–10 weeks, were acclimatized for two weeks in a temperature- 
and light-controlled room two mice per cage (Eurostandard Type IIL), with ad libitum access to tap water and 
standard pellet chow. At day 0, diets were changed to a diet containing 0.05% (w/w) MgO (#S9074-E1107, Ssniff 
Spezialdiäten, GmbH, Germany) and drinking water to demineralized water. At days-2, 12 and 26 mice were 
housed individually in metabolic cages for 48 hours (24 hours adaptation, 24 hours collection) to measure food 
and water intake and to collect urine and feces. Mice were weighed twice weekly and blood was collected via the 
submandibular vein at days -2 and 15. Mice were randomly divided into four experimental groups of ten mice 
per group, of which half received metformin hydrochloride (0.5 mg/ml, Sigma Aldrich, MI, USA), dispersed in 
the drinking water. Researchers and animal caretakers were blinded for the metformin treatment. After 28 days of 
treatment, mice were anaesthetized by 4% (v/v) isoflurane and exsanguinated by orbital sinus bleeding, and death 
was confirmed by cervical dislocation. Colon and kidney tissues were cleaned with ice-cold PBS and snap-frozen 
in liquid nitrogen.
RT-qPCR. TRIzol reagent (Invitrogen, Bleiswijk, the Netherlands) was used to extract total RNA from kid-
ney and distal colon according to the manufacturer’s protocol. RNA was subjected to DNase (Promega, the 
Netherlands) treatment at 37 °C for 30 min and then to DNase stop buffer at 65 °C for 10 min. The RNA con-
centration was measured using the Nanodrop 2000c (Thermoscientific, Wilmington, DE). To synthetize cDNA, 
1.5 µg of total RNA was reverse transcribed for 1 hour at 37 °C using Moloney-Murine Leukemia Virus (M-MLV) 
reverse transcriptase (Invitrogen, Bleiswijk, the Netherlands). SYBR Green Supermix (BioRad, Veenendaal, the 
Netherlands) was used to analyze the gene expression levels on a BioRad (Hercules, CA, USA) analyzer. After 
normalizing to housekeeping gene expression (Hprt), the relative gene expression was calculated by the Livak 
method (2−∆∆ct). Primers sequences are provided in Table 1.
Analytical measurements. Serum and urinary Mg2+ concentrations were determined using a spectropho-
tometric assay (Roche/Hitachi, Tokyo, Japan), according to manufacturer’s protocol. Ca2+ concentrations were 
determined by the o-cresophthalein complexone method. Absorbance for the Mg2+ and Ca2+ assays was meas-
ured at 600 nm and 570 nm, respectively, on a Bio-Rad Benchmark plus microplate spectrophotometer (Bio-Rad 
Laboratories, CA, USA). Serum and urinary Na+ and K+ concentrations were measured at the clinical chemistry 
department applying standardized methods1. Serum and urinary glucose concentrations were determined by a 
spectrophotometric assay according to the manufacturer’s protocol (Instruchemie, Delfzijl, the Netherlands).
statistical analyses. Interaction between the two main variables (genotype and treatment) was investi-
gated using a two-way ANOVA test. If there was a significant interaction effect, an unpaired multiple t test, with 














Table 1. Primer sequences used for RT-qPCR. Cldn10b, claudin 10b; Cldn14, claudin 14; Cldn16, claudin 
16; Cldn19, Claudin 19; Cnnm4, cyclin M4; Fxyd2, FXYD-domain containing 2; Hprt, hypoxanthine-guanine 
phosphoribosyltransferase; Slc12a1, solute carrier family 12 member 1; Slc12a3, solute carrier family 12 member 3; 
Slc41a1, solute carrier family 41 member 1; Slc41a3, solute carrier family 41 member 3; Trpm6, transient receptor 
potential melastatin type 6; Trpm7, transient receptor potential melastatin type 7.
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the Holm–Sidak method for multiple comparisons, was used. In the absence of a significant interaction effect, 
a two-way ANOVA approach with a Tukey’s multiple comparisons test was used. Statistical significance was 
assessed using Graphpad Prism v7 (La Jolla, CA, USA, RRID: SCR_002798. A p-value of ≤0.05 was considered 
statistically significant. Results are presented as mean ± SEM.
Results
Metformin reduces food intake of db/db mice without affecting body weight. To investigate how 
T2D and its first-line treatment metformin affect Mg2+ homeostasis, control (db/m) and diabetic (db/db) mice 
were treated with metformin or placebo for four weeks. Db/db mice were significantly heavier than db/m mice 
(Fig. 1a,b; 27.0 ± 0.3 vs. 45.6 ± 0.6 gr. for db/m and db/db mice at four weeks, respectively, p ≤ 0.05). Metformin 
treatment had no effect on body weight in both db/m and db/db mice (Fig. 1a,b). Metformin treatment reduced 
the food intake only in the db/db mice (Fig. 1c). The lower food intake was accompanied by a decreased feces 
weight, water intake and urinary volume in the metformin-treated db/db mice (Fig. 1d–f). Metformin did not 
influence non-fasting serum glucose levels in both genotypes (Fig. 1g). However, the glycosuria of the db/db mice 
was attenuated by metformin treatment (Fig. 1h).
Db/db mice have reduced serum Mg2+ concentrations. Serum Mg2+ concentrations were lower in db/
db than db/m mice at two weeks (Fig. 2a, 1.17 ± 0.04 vs. 0.88 ± 0.04 mmol/L in db/m vs. db/db placebo-treated 
mice, respectively, Holm-Sidak’s multiple comparison p ≤ 0.05) and four weeks (Fig. 2b, 1.10 ± 0.05 vs. 
0.95 ± 0.04 mmol/L in db/m vs. db/db placebo-treated mice, respectively, Holm-Sidak’s multiple comparison 
p ≤ 0.05). At two weeks, there was a significant genotype effect on urinary Mg2+ excretion, demonstrating an 
increased urinary Mg2+ loss in db/db mice (Fig. 2c, 6.8 ± 0.6 vs. 8.6 ± 0.6 µmol/24 h in db/m vs. db/db mice, 
respectively, two-way ANOVA p ≤ 0.05), whereas no significant difference was observed at four weeks (Fig. 2d). 
At four weeks, the serum Ca2+ concentration was higher in db/db compared to db/m mice, indicated by a sig-
nificant genotype effect (Fig. 2e, 1.28 ± 0.05 vs. 1.46 ± 0.06 mmol/L Ca2+ in db/m vs. db/db mice, respectively, 
two-way ANOVA p ≤ 0.05). There were no significant differences on urinary Ca2+ excretion (Fig. 2f). Despite the 
higher food intake of db/db animals, a significant genotype effect demonstrated lower serum Na+ levels in db/db 
compared to db/m mice (Fig. 2g, 167 ± 2 vs. 159 ± 3 mmol/L Na+ in db/m vs. db/db mice, respectively, two-way 
ANOVA p ≤ 0.05). Urinary excretion of Na+ and K+ was higher in db/db than db/m mice, and metformin treat-
ment reduced Na+ and K+ excretion only in db/db mice (Fig. 2h,j). Serum K+ concentrations were not different 
between all experimental groups (Fig. 2i).
Db/db mice have an enhanced colonic expression of Trpm6. When serum Mg2+ levels decrease, 
intestinal uptake of Mg2+ is enhanced15. Colonic mRNA expression of Trpm6, the major channel for regulated 
Mg2+ absorption, was elevated in db/db compared to db/m mice (Fig. 3a). There was no difference in mRNA 
expression of the ubiquitous Mg2+ channel Trpm7 and of the Mg2+ transport regulator Cyclin m4 (Cnnm4) 
(Fig. 3b,c). The colonic gene expression of the basolateral Mg2+ transporter solute carrier family 41 (Slc41a1) was 
lower in both db/db groups (Fig. 3d).
Db/db mice have an elevated renal expression of genes involved in Mg2+ handling. Db/db mice 
had an enhanced gene expression of the DCT-specific apical Mg2+ channel Trpm6, and the basolateral Mg2+ 
extruder Slc41a3 (Fig. 4a,b). While both db/db groups showed a higher expression of Slc12a3, encoding for NCC, 
metformin further enhanced the expression of this gene in db/db mice (Fig. 4c). The driving force for paracellular 
Mg2+ uptake in the TAL is generated by NKCC2, encoded by Slc12a1, which is expressed higher in db/db mice 
(Fig. 4d). A significant genotype effect indicated a decreased expression of Claudin 10b (Cldn10b) in db/db mice 
(Fig. 4e, 1.00 ± 0.05 vs. 0.83 ± 0.02 relative gene expression in db/m vs. db/db mice, two-way ANOVA p ≤ 0.05). 
In contrast, the mRNA expression of Cldn14, Cldn16 and Cldn19 was enhanced in db/db mice (Fig. 4f–h). The 
gene expression of the ubiquitous Mg2+ channel Trpm7 was elevated in the placebo-treated db/db mice and 
the expression of Fxyd2, encoding for the gamma subunit of the Na+-K+-ATPase, was enhanced in both db/db 
groups (Fig. 4i,j).
Discussion
Hypomagnesemia is a common clinical feature in T2D patients1,3. Metformin use is associated with a lower blood 
Mg2+ concentration in these patients1,26. In this study, db/db mice developed hypomagnesemia with compensa-
tory upregulation of key renal and colonic magnesiotropic genes. Metformin treatment had no effect on Mg2+ 
homeostasis in either control or diabetic mice. Our data demonstrate that hypomagnesemia is a consequence of 
T2D and is not modulated by metformin treatment in mice.  INSERT ENTER Metformin is the first-line therapy 
for T2D27. In large-scale observational cohort studies metformin-use is associated with lower serum Mg2+ levels 
and reduced renal Mg2+ wasting in T2D patients1,26,28–30. In a small intervention study in T2D patients, metformin 
treatment resulted in a minor reduction in the serum Mg2+ concentration (from 0.72 to 0.70 mmol/L), despite 
major improvements in the blood glucose concentration29. In our study, metformin treatment did not affect the 
serum Mg2+ concentration and urinary Mg2+ excretion in db/db and db/m mice. In addition, metformin did not 
alter gene expression of colonic and renal Mg2+ transporters. This is in line with a study that observed no effect 
of a two-week metformin treatment on serum Mg2+ levels in streptozotocin-induced diabetic rats31. Possibly, a 
two- to four-week treatment duration is too short to detect effects on Mg2+ homeostasis. The association between 
metformin and lower serum Mg2+ levels in T2D patients could also be caused by other factors that were not 
included in the analyses. For instance, a well-known side effect of metformin-treatment is chronic diarrhea, lead-
ing to intestinal malabsorption and hypomagnesemia28.
Hypomagnesemia is prevalent in over 30% of T2D patients32–35. A remaining question is whether hypomag-
nesemia is the cause or the consequence of T2D8. In the present study, db/db mice developed hypomagnesemia, 
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Figure 1. Metformin treatment does not affect body weight, but reduces food intake and urinary glucose 
excretion in db/db mice. Db/m and db/db mice were treated with metformin for four weeks. (a) Body weight 
of the animals, measured twice weekly and on the days of the metabolic cage experiments. Triangles, db/m 
mice; circles, db/db mice; open symbols, placebo-treated mice; closed symbols, metformin-treated mice. (b) 
Body weight at the end of the experiment, after four weeks of treatment. (c) Food intake, (d) total feces weight, 
(e) water intake and (f) urinary volume determined over a period of 24 hours, using metabolic cages, after four 
weeks of treatment. (g) Non-fasted serum glucose concentration and (h) 24-hour urinary glucose excretion 
after four weeks of treatment. Open bars, placebo-treated mice; closed bars, metformin-treated mice. Data are 
mean ± SEM. Depending on the absence or presence of a significant interaction effect between genotype and 
treatment, either a two-way ANOVA (Tukey’s multiple comparison test) or an unpaired multiple t test (Holm-
Sidak multiple comparison test) approach, respectively, was used to determine statistical significance. *Indicates 
a p ≤ 0.05.
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Figure 2. Db/db mice have a lower serum Mg2+ concentration which is not modulated by metformin 
treatment. (a) Serum Mg2+ concentration after two weeks of treatment and (b) after four weeks of treatment. 
(c) 24-Hour urinary Mg2+ excretion after two weeks of treatment (6.8 ± 0.6 vs. 8.6 ± 0.6 µmol/24 h in db/m 
vs. db/db mice, respectively, two-way ANOVA p ≤ 0.05) and (d) after four weeks of treatment. (e) Serum Ca2+ 
concentration (1.28 ± 0.05 vs. 1.46 ± 0.06 mmol/L Ca2+ in db/m vs. db/db mice, respectively, two-way ANOVA 
p ≤ 0.05) and (f) 24-hour urinary Ca2+ excretion, after four weeks of treatment. (g) Serum Na+ concentration 
(167 ± 2 vs. 159 ± 3 mmol/L Na+ in db/m vs. db/db mice, respectively, two-way ANOVA p ≤ 0.05) and (h) 
24-hour urinary Na+ excretion, after four weeks of treatment. (i) Serum K+ concentration and (j) 24-hour 
urinary K+ excretion, after four weeks of treatment. Open bars, placebo-treated mice; closed bars, metformin-
treated mice. Data are mean ± SEM. Depending on the absence or presence of a significant interaction effect 
between genotype and treatment, either a two-way ANOVA (Tukey’s multiple comparison test) or an unpaired 
multiple t test (Holm-Sidak multiple comparison test) approach, respectively, was used to determine statistical 
significance. *Indicates a p ≤ 0.05.
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indicating that hypomagnesemia is a consequence of T2D. At the fourth week of the experiment, db/db mice 
developed massive glycosuria but no renal Mg2+ wasting. This finding is against the leading hypothesis that renal 
Mg2+ wasting in T2D patients is a result of glycosuria2,3,36. Indeed, metformin treatment noticeably decreased 
glycosuria in db/db mice but did not modify the urinary Mg2+ excretion. This is in line with recent observa-
tions that glycosuria-causing SGLT2 inhibitors, lead to a mild increase in serum Mg2+ levels37,38. Therefore, it is 
unlikely that glycosuria underlies hypermagnesuria-induced hypomagnesemia in T2D. As db/db mice develop 
severe hyperinsulinemia, the observed hypomagnesemia could be a consequence of a Mg2+-shift towards the 
intracellular compartment, induced by insulin39–41. Future studies should focus on measuring intracellular Mg2+ 
concentrations in diabetic mice.
The kidneys are essential in maintaining the serum Mg2+ concentration within the physiological range15. The 
DCT is the final segment where Mg2+ can be reabsorbed9. In the DCT, regulated Mg2+ reabsorption takes place 
transcellularly via TRPM618. Mg2+ uptake by TRPM6 is dependent on NCC, although the underlying mechanism 
remains largely unknown42,43. Gene expression levels of Trpm6 and Slc12a3, encoding for NCC, were enhanced in 
db/db mice, indicative of compensation in the DCT. As only a minor hypermagnesuria is observed at two-weeks, 
and no hypermagnesuria at four-weeks, there appears to be proper renal compensation in the db/db mice. The 
TAL is responsible for the bulk of renal Mg2+ reabsorption9. In the TAL, paracellular Mg2+ and Ca2+ reabsorption 
is regulated by the Cldn14/16/19 complex44,45. Cldn14 mRNA expression is strongly regulated by dietary Ca2+ 
intake46,47. The high food intake, and therefore high Ca2+ intake, of db/db mice is likely the underlying cause of 
the extensive upregulation of Cldn14 expression. The high expression of Cldn14 will have a negative effect on 
Mg2+ reabsorption in the TAL, leading to a compensatory increase in Cldn16/19 expression48. In contrast, gene 
expression of Cldn10b was decreased. Cldn10b enhances the Na+-permeability of the TAL, and thereby indirectly 
increases uptake of Mg2+ and Ca2+ in the TAL. Therefore, Cldn10b-deficient mice develop hypermagnesemia and 
hypomagnesuria. Likely, the observed reduction in Cldn10b expression in the db/db mice is a response to the 
high osmolality of the pro-urine. INSERT ENTER The strength of this study is that using oral metformin treat-
ment in diabetic mice closely resembles the human situation. Db/db mice developed hypomagnesemia making 
them an excellent model to study the mechanisms of hypomagnesemia in T2D. Moreover, this study extensively 
investigated differences in expression of all known genes involved in Mg2+ transport, in both kidney and colon. 
Some limitations have to be considered. The fact that metformin treatment did not affect Mg2+ homeostasis raises 
the question whether the dose and duration of metformin treatment were sufficient. However, the metformin 
treatment reduced the food intake of db/db mice, a known positive effect of metformin. Moreover, the dosage 
of metformin that the db/db received (0.5 mg/ml, equivalent to a daily intake of approximately 165 mg/kg bod-
yweight) is similar to previous studies investigating the metabolic effects of metformin in mice49–52. A second 
Figure 3. Upregulation of Trpm6 mRNA expression in the colon of db/db mice. mRNA expression of key 
magnesiotropic genes in distal colon (a) Trpm6, (b) Trpm7, (c) Cnnm4 and (d) Slc41a1. Open bars, placebo-
treated mice; closed bars, metformin-treated mice. Data are mean ± SEM. Depending on the absence or 
presence of a significant interaction effect between genotype and treatment, either a two-way ANOVA (Tukey’s 
multiple comparison test) or an unpaired multiple t test (Holm-Sidak multiple comparison test) approach, 
respectively, was used to determine statistical significance. *Indicates a p ≤ 0.05.
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limitation is that the expression of genes such as Cldn10b/14, Slc12a1 and Slc12a3 is regulated by both dietary 
intake and serum levels of K+, Na+ and Ca2+ 43,44,53. As db/db mice have hyperphagia, their dietary intake of ions 
is also increased. Despite the higher food intake, db/db mice still develop hypomagnesemia. However, for other 
Figure 4. Upregulation in the expression of essential renal magnesiotropic genes in db/db mice. mRNA 
expression of genes involved in renal electrolyte handling (a) Trpm6, (b) Slc41a3, (c) Slc12a3, (d) Slc12a1, 
(e) Cldn10b (1.00 ± 0.05 vs. 0.83 ± 0.02 relative gene expression in db/m vs. db/db mice, two-way ANOVA 
p ≤ 0.05), (f) Cldn14, (g) Cldn16, (h) Cldn19, (i) Trpm7 and (j) Fxyd2. Open bars, placebo-treated mice; closed 
bars, metformin-treated mice. Data are mean ± SEM. Depending on the absence or presence of a significant 
interaction effect between genotype and treatment, either a two-way ANOVA (Tukey’s multiple comparison 
test) or an unpaired multiple t test (Holm-Sidak multiple comparison test) approach, respectively, was used to 
determine statistical significance. *Indicates a p ≤ 0.05.
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differences between db/m and db/db mice it is difficult to differentiate whether they are caused by T2D-related 
factors or by a higher food intake.
In conclusion, hypomagnesemia is a consequence of T2D, which is not affected by metformin treatment. The 
reason that metformin-users have lower serum Mg2+ concentrations is likely mediated by other factors, and not 
by a direct effect of metformin on Mg2+ (re)absorption.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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